• Journal of Pharmaceutical Investigation
• /
• v.37 no.6
• /
• pp.359-364
• /
• 2007

Pine bark extract is well-known as a very powerful antioxidant, anti-inflammatory, and antibiotic material. French maritime pine bark extract ($Pycnogenol^{(R)}$) of Horphag Research has monopolized the world market over 30 years. Korean red pine bark extract ($Pinexol^{(R)}$) was first manufactured by the patent technology of NutraPharm in Korea in 2006. Feasibility of topical gel and patch formulations of Pinexol was systematically investigated by evaluating the skin absorption of catechin as a reference compound. In vitro hairless mouse skin absorption of catechin from gel formulation was higher than that from patches. However, significant amount of catechin was also deposited inside the skin from patch formulations, which were dependent on the types of pressure sensitive adhesives. Thus, it seems to be feasible to control the topical delivery of Pinexol by using both gel and patch formulations, and be necessary to conduct further systematic investigation.

• YAKHAK HOEJI
• /
• v.45 no.5
• /
• pp.506-512
• /
• 2001

Ketoprofen (KP) was formulated as a transdermal patch using the percutaneous penetration enhancers sorbitan monmmleate(SMO), polyvinylpyrrolidone(PVP). The control patch without penetration enhancers showed a KP flux of 8.9$\pm$0.75$\mu\textrm{g}$/$\textrm{cm}^2$/h The flux was increased in proportion to the concentration of SMO added. Furthermore, lag times were decreased upon addition of SMO. Conversely; the skin flux of KP was decreased in proportion to the concentration of PVP added. Pharmacokinetic parameters including $C_{max}$, $T_{max}$, and AUC were increased when SMO was added. However, $C_{mas}$ significantly decreased by the addition of PVP. $T_{max}$ was not significantly different in 2%, 4%, and 8% PVP patches. Patches containing 4% PVP showed the highest AUC value (19.158$\mu\textrm{g}$.h/ml). We found that the effectiveness of the two percutaneous penetration enhancers for topical KP patches was similar, with the addition of appropriate amounts of HPC modifying both skin flux and lag time of KP in the patches. In conclusion, it is possible to manufacture KP patches exhibiting high AUC, high skin flux, and short lag time using percutaneous penetration enhancers of SMO and PVP.

• Journal of Radiation Industry
• /
• v.17 no.4
• /
• pp.327-332
• /
• 2023

This study identified effects of Isoegomaketone for applicable patch on the arthritis in mice. Isoegomaketone (IK) was isolated from Perilla frutescens, which is annual herbal traditional medicinal, aromatic, functional food. IK has various physiological effects such as anti-inflammation, anti-oxidant, and anti-cancer. In the previous study, oral administration of IK to a mouse model of collagen antibody-induced arthritis(CAIA), which is similar to human rheumatoid arthritis(RA), alleviated symptoms. In this study, we attached a patch containing IK to mouse skin to demonstrate whether it had the same efficacy as oral administration in CAIA mouse. As a result of measuring the arthritis score, paw volume, and paw thickness, it was confirmed that arthritis symptoms were alleviated in the group to which the patch containing IK was attached. These results show that IK is effective in alleviating arthritis not only through oral administration but also through patches applied to skin, and that it has potential as a material for future patch development.

• Polymer(Korea)
• /
• v.33 no.3
• /
• pp.237-242
• /
• 2009

This study examined the transdermal delivery of alendronate across hairless mouse skin. The effects of iontophoresis, perforation with a microneedle, and a combination of a microneedle pretreatment and iontophoresis were evaluated in vitro test. Hydrogel patches were polymerized by UN polymerization to supply a hydrogel patch to the iontophoretic transdermal drug delivery system. The alendronate content in the iontophoretic delivery patch was $5.0\;mg/cm^3$. The amounts of alendronate that permeated across the hairless mouse skin when current densities of 0.25 and $0.50\;mA/cm^2$ were supplied to the iontophoretic alendronate patch were $0.80{\pm}0.03$ and $2.00{\pm}0.02{\mu}g$, respectively. After pretreatment with a microneedle, the amounts of alendronate that permeated across the hairless mouse skin increased to $70.65{\pm}0.37$ and $162.23{\pm}0.40{\mu}g$, respectively. The biocompatibility of the iontophoretic alendronate patch was examined according to the international standardization organization 10993.

• Journal of the Society of Cosmetic Scientists of Korea
• /
• v.46 no.3
• /
• pp.219-229
• /
• 2020

Recently, since atopic dermatitis is sensitive to skin irritation, it has been suggested that the development of a patch that can effectively exhibit adhesion and absorption to a specific local area while minimizing skin irritation, and capable of appropriate drug release should be given priority. In this study, we tried to develop a hydrogel patch that minimizes skin irritation, adheres effectively to a specific area, and promotes absorption. The atopic patch was formulated into a super-absorbent hydrogel sheet using a freeze drying method. Cell viability assay was carried out using keratinocytes (HaCaT cell) and fibroblasts (L929 cells). In order to investigate the physical properties, FT-IR, FE-SEM, porosity analysis and swelling behavior were investigated. As a result, the newly prepared HA-Dex hydrogel patch was verified by biocompatibility and physical evaluation. In addition, the manufactured hydrogel patch has sufficient moisture absorption capacity and can relieve itching of atopic skin, and is expected to be applied to various drug delivery products for the treatment of atopic dermatitis in the future.

• YAKHAK HOEJI
• /
• v.44 no.2
• /
• pp.189-192
• /
• 2000

We examined a dermal pharmacokinetics for a new SYC-fentanyl patch in rabbits. Determination of fentanyl in the plasma was performed using a gas chromatography with nitrogen-phosphorus detection system and a capillary column. One patch per animal (fentanyl 2.5 mg) was applied to clipped back skin for 72 hours. The plasma fentanyl concentration profile of SYC-patch was similar to that of a conventional patch (Durogesi $c^{R}$, Janssen Co.). No significant difference was observed in the pharmacokinetic parameters, the area under the concentration-time curve (AU $C^{0-}$72hrs/) and the total area under the first moment-time curve (AUM $C^{0-}$7hrs/), between the two patch types. The AU $C^{0-}$7hrs/ and AUM $C^{0-}$72hrs/ of durogesi $c^{R}$ were 183.3$\pm$46.28 ng＊hr/ml and 6,450$\pm$1,939ng＊h$r^2$/ml, and those of SYC-fentany patch were 217.2$\pm$50.51$\pm$ng＊hr/ml and 8,022$\pm$2,245ng＊h$r^2$/ml, respectively (n=3). This result indicates that the new SYC patch has a similar bioavailability compared to durogesi $c^{R}$ patch. Therefore, the SYC-patch may be considered as a bioequivalent fentanyl patch.patch.tch.

• Toxicological Research
• /
• v.29 no.2
• /
• pp.87-90
• /
• 2013

The potential role of topical valproate (VPA) in hair regrowth has been recently suggested. However, safety reports of VPA as a topical formulation are lacking. Therefore, in the present study, we investigated whether VPA causes skin irritation in humans. We first performed a cell viability test and showed that VPA did not exhibit toxicity toward HaCaT keratinocytes, fibroblasts, and RBL-3H mast cells. We then performed clinical patch test and skin irritation test through transdermal drug delivery with the help of microneedle rollers. No significant findings were obtained in the clinical patch test. In the skin irritation test, only 1 patient showed erythema at 1 hr, but the irritation reaction faded away within a few hours. Erythema and edema were not observed at 24 hr. We concluded that VPA has minimal potential to elicit skin irritation. Therefore, we consider that VPA can safely be applied to human skin.

• Journal of the Korean Society of Manufacturing Process Engineers
• /
• v.18 no.7
• /
• pp.71-76
• /
• 2019

The diffusion of the drug component of the inflammatory patch into the living tissue was analyzed by laser induced plasma spectroscopy (LIBS). Calcium element, which is a diffusion catalyst of the drug in the inflammatory analgesic patch, is transferred into the body through the diffusion process of the substance. The test pieces used in the experiment are pig skin tissues which are similar to human skin. As a result, the diffusion coefficient D of the calcium element was found to be average $8.24{\times}10^{-2}({\mu}m^2/s)$. Experimental results showed that the most influential factors on the diffusion of materials were temperature variables.

• Journal of Pharmaceutical Investigation
• /
• v.36 no.2
• /
• pp.97-102
• /
• 2006

The aim of this study was to investigate the feasibility and optimize permeability of slim patch type as a transdermal delivery system of caffein. Slim patch type was formulated and tested in modified Franz diffusion cell across cellulose membrane and hairless mouse skin in pH 5.8 phosphate buffer solution (PBS). The effect of $Pharmsolv^{\circledR}$ and drug concentration on permeation at four model, 1,2% $Pharmsolv^{\circledR}$ with $0.12\;mg/cm^2$ caffein and 0.12, $1.2\;mg/cm^2$ caffein with 2% $Pharmsolv^{\circledR}$ through hairless mouse skin was studied in vitro. The release of caffein from slim patch with various loading was fitted by the Higuchi's diffusion equation. The result showed that chemical $Pharmsolv^{\circledR}$ produced a large and significant increase of permeation. The effect of 2% $Pharmsolv^{\circledR}$ on permeation of caffein was greater about 10-fold greater than 1% $Pharmsolv^{\circledR}$ in first 60 minutes. The effect of drug concentration, however, was lower than that produced by chemical $Pharmsolv^{\circledR}$. Within the tested system, the most efficient combination for caffein slim patch type was $0.12\;mg/cm^2$ caffein with 2% $Pharmsolv^{\circledR},$ although $1.2\;mg/cm^2$ caffein with 2% $Pharmsolv^{\circledR}$ showed highest amounts permeation, because permeated percentages were significantly lower about $1/4{\sim}1/5$ times.

• Korean Journal of Pharmacognosy
• /
• v.48 no.3
• /
• pp.202-207
• /
• 2017

The purpose of this study was to investigate the skin irritation of bee venom (melittin) in human. Skin irritation test was performed at 0.05% bee venom by 48 h single patch test in 30 healthy volunteers with no skin disease and skin sensitization test was performed by local lymph node assay in animal. In single patch test, 28 human subjects showed no reaction and 2 subjects showed 1+ or 3+ grade skin reaction. In a skin sensitization test of bee venom conducted using mice. no erythema was observed on the dorsal side of mice up to 8 days after application of bee venom on the skin. The results of the average stimulation index by ATP values showed that there was no irritation to the mice skin at 0.005% and 0.01% of bee venom. Therefore, bee venom is not likely to induce a significant skin irritation under 0.05% concentration.